These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 2923448)

  • 1. Treatment of malignant carcinoid syndrome with a long-acting somatostatin analogue.
    Altman AR; Tschen JA; Rice L
    Arch Dermatol; 1989 Mar; 125(3):394-6. PubMed ID: 2923448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Symptomatic treatment of the malignant carcinoid syndrome with octreotide].
    Alberts AS; Falkson G
    S Afr Med J; 1989 Jan; 75(1):30-1. PubMed ID: 2911781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A prolonged-action somatostatin analog and carcinoid syndrome].
    Chayvialle JA
    Bull Acad Natl Med; 1989 May; 173(5):643-50; discussion 650-1. PubMed ID: 2478266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A favorable response to the somatostatin analog SMS 201-995 in a patient with the carcinoid syndrome].
    Del Val A; Ponce J; Talens A; Martí-Bonmati L; Garrigues V; Berenguer J
    Rev Esp Enferm Dig; 1991 Mar; 79(3):215-7. PubMed ID: 2043408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of carcinoid syndrome with a somatostatin analogue].
    Döbrönte Z; Stöckert A; Végh G; Varga L
    Orv Hetil; 1992 Mar; 133(12):731-4. PubMed ID: 1372969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.
    Kvols LK; Moertel CG; O'Connell MJ; Schutt AJ; Rubin J; Hahn RG
    N Engl J Med; 1986 Sep; 315(11):663-6. PubMed ID: 2427948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatostatin and a long-acting analogue, octreotide acetate. Relevance to dermatology.
    Camisa C
    Arch Dermatol; 1989 Mar; 125(3):407-12. PubMed ID: 2564269
    [No Abstract]   [Full Text] [Related]  

  • 8. [Carcinoid tumor--diagnostic and therapeutic problems].
    Batowski S; Bielewicz A
    Pol Tyg Lek; 1994 Jun 6-13; 49(23-24):536-7. PubMed ID: 7675710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome.
    Saslow SB; O'Brien MD; Camilleri M; von der Ohe M; Homburger HA; Klee GG; Pitot HC; Rubin J
    Am J Gastroenterol; 1997 Dec; 92(12):2250-6. PubMed ID: 9399764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Octreotide treatment of carcinoid hypertensive crisis.
    Warner RR; Mani S; Profeta J; Grunstein E
    Mt Sinai J Med; 1994 Sep; 61(4):349-55. PubMed ID: 7969229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uneventful spinal anesthesia for a patient with carcinoid syndrome managed with long-acting octreotide.
    Orbach-Zinger S; Lombroso R; Eidelman LA
    Can J Anaesth; 2002; 49(7):678-81. PubMed ID: 12193484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Enteral hyperoxalosis due to therapy with a somatostatin analog].
    Ranft K; Eibl-Eibesfeldt B
    Dtsch Med Wochenschr; 1990 Feb; 115(5):179-81. PubMed ID: 2298134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of carcinoid syndrome with ocreotide (SMS-201-995)].
    Rodríguez-García JL; Arechaga S; Fraile G; Serrano M
    Rev Clin Esp; 1992 Jul; 191(3):168. PubMed ID: 1380173
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful symptomatic treatment of malignant carcinoid syndrome with the somatostatin analogue SMS 201-995.
    van Houten AA; Nortier JW; Vendrik CP
    Neth J Med; 1988 Apr; 32(3-4):194-8. PubMed ID: 2896307
    [No Abstract]   [Full Text] [Related]  

  • 15. The carcinoid syndrome.
    Maton PN
    JAMA; 1988 Sep; 260(11):1602-5. PubMed ID: 2457717
    [No Abstract]   [Full Text] [Related]  

  • 16. [Carcinoid syndrome with a course of more than 10 years].
    Baur X; Bortsch A; Autenrieth G; Jacob K; Neudert J; Schneider B; Werdan K
    Internist (Berl); 1988 May; 29(5):347-50. PubMed ID: 2900222
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of a patient with carcinoid syndrome with SMS-201-995 (octreotide) for 32 months].
    Marcos Sánchez F; Juárez Ucelay F; Plaza Díaz R; García Camba L; Durán Pérez-Navarro A
    An Med Interna; 1993 Jun; 10(6):309. PubMed ID: 8334213
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical features of carcinoid syndrome and the use of somatostatin analogue in its management.
    Vinik AI; Thompson N; Eckhauser F; Moattari AR
    Acta Oncol; 1989; 28(3):389-402. PubMed ID: 2663049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of the administration of somatostatin 14 in the carcinoid syndrome. Clinical and biological study of 2 cases].
    Guillard JF; Galmiche JP; Chayvialle JA; Kremer M; Comoy E; Lerebours E; Charbonnel B; Colin R
    Gastroenterol Clin Biol; 1983 Dec; 7(12):1016-22. PubMed ID: 6141119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic principles in the management of metastasising carcinoid tumors: drugs for symptomatic treatment.
    Gregor M
    Digestion; 1994; 55 Suppl 3():60-3. PubMed ID: 7698539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.